AR125120A1 - Actividad antiviral de inhibidores de vps34 - Google Patents

Actividad antiviral de inhibidores de vps34

Info

Publication number
AR125120A1
AR125120A1 ARP210103257A ARP210103257A AR125120A1 AR 125120 A1 AR125120 A1 AR 125120A1 AR P210103257 A ARP210103257 A AR P210103257A AR P210103257 A ARP210103257 A AR P210103257A AR 125120 A1 AR125120 A1 AR 125120A1
Authority
AR
Argentina
Prior art keywords
c3alkyl
group
c3alkoxyc1
c6alkyl
optionally substituted
Prior art date
Application number
ARP210103257A
Other languages
English (en)
Inventor
Daniel L Flynn
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of AR125120A1 publication Critical patent/AR125120A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Métodos de tratamiento de infecciones virales, tales como infecciones por coronavirus, en pacientes que lo necesitan, que comprenden administrar a dichos pacientes un inhibidor de VPS34. Reivindicación 1: Un método para paliar o tratar una infección viral en un paciente que lo necesite, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, donde: X se selecciona entre -C(=O)- y un enlace; R¹ se selecciona entre el grupo que consiste en H, C₁-C₃alquilo, C₁-C₃haloalquilo, C₁-C₃alcoxiC₁-C₃alquilo, C₃-C₆cicloalquilo, C₃-C₆ciclohaloalquilo, C₁-C₃alcoxi, C₁-C₃haloalcoxi, C₃-C₆cicloalcoximetilo, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino, 1-pirrolidinilo, 1-piperidinilo y 1-azetidinilo, con la condición de que cuando R¹ se selecciona entre el grupo que consiste en C₁-C₃alcoxi, C₁-C₃haloalcoxi, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino, 1-pirrolidinilo, 1-piperidinilo, y 1-azetidinilo, entonces X es C=O; R² se selecciona entre el grupo que consiste en H, C₁-C₃haloalquilo, y C₁-C₃alquilo; R³ se selecciona entre el grupo que consiste en A, fenilo y heteroarilo monocíclico, donde cada fenilo y heteroarilo monocíclico está opcionalmente sustituido con una o más instancias de un sustituyente seleccionado en forma independiente entre el grupo que consiste en R⁴, R⁵, R⁶ y R⁷; cada R⁴, R⁵, R⁶, y R⁷ se selecciona en forma independiente entre el grupo que consiste en halo, C₁-C₆alquilo, C₃-C₆cicloalquilo, C₁-C₆alcoxi, C₁-C₃haloalcoxi, N,N-diC₁-C₃alquilamino, N-C₁-C₃alquilamino, 1-azetidinilo, C₁-C₆haloalquilo, amino, NHSO₂R⁸, SO₂R⁹, e hidroxi; R⁸ se selecciona entre C₁-C₃haloalquilo y C₁-C₃alquilo; cada R⁹ se selecciona en forma independiente entre el grupo que consiste en R¹⁰, C₁-C₆alquilo, amino, N-C₁-C₃alquilamino, N,N-di-C₁-C₃alquilamino y C₁-C₃alcoxiC₁-C₃alquilo, donde cada uno de C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una instancia de R¹⁰, y cada C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una o más instancias independientes de halógeno; cada R¹⁰ se selecciona en forma independiente entre el grupo que consiste en fenilo, heteroarilo monocíclico, C₃-C₆cicloalquilo, y heterociclilo, donde cada fenilo, heteroarilo monocíclico, C₃-C₆cicloalquilo, y heterociclilo está opcionalmente sustituido con una o más instancias de R¹¹; cada R¹¹ se selecciona en forma independiente entre el grupo que consiste en halo, C₁-C₃alcoxiC₁-C₃alquilo, amino, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino, C₁-C₃haloalcoxi, C₁-C₃alcoxi, C₃-C₆cicloalquilo, C₁-C₃haloalquilo, y C₁-C₃alquilo; A es: un compuesto de fórmula (2); R¹² se selecciona entre el grupo que consiste en H, halo, COR¹³, C₁-C₆alquilo, C₁-C₃alcoxiC₁-C₃alquilo, C₁-C₆alcoxi, C₃-C₆cicloalquilo, C₁-C₃cianoalquilo, y C₁-C₃haloalquilo; R¹³ se selecciona entre el grupo que consiste en C₁-C₃alcoxi, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino, 1-pirrolidinilo, 1-piperidinilo, y 1-azetidinilo; Y se selecciona entre el grupo que consiste en CH₂, S, SO, SO₂, NR¹⁴, NCOR⁹, NCOOR¹⁵, NSO₂R⁹, NCOCH₂R⁹, O, y un enlace; R¹⁴ se selecciona entre el grupo que consiste en H, C₁-C₃haloalquilo, C₁-C₃alcoxiC₁-C₃alquilo, C₁-C₃alquilo, y C₃-C₆cicloalquilo; y R¹⁵ se selecciona entre el grupo que consiste en R¹⁰, C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo, donde cada uno de C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una instancia de R¹⁰, y cada C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una o más instancias independientes de halógeno.
ARP210103257A 2020-11-25 2021-11-25 Actividad antiviral de inhibidores de vps34 AR125120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063118520P 2020-11-25 2020-11-25

Publications (1)

Publication Number Publication Date
AR125120A1 true AR125120A1 (es) 2023-06-14

Family

ID=80781052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103257A AR125120A1 (es) 2020-11-25 2021-11-25 Actividad antiviral de inhibidores de vps34

Country Status (8)

Country Link
US (1) US11801238B2 (es)
EP (1) EP4251152A1 (es)
JP (1) JP2023553809A (es)
CN (1) CN117083064A (es)
AR (1) AR125120A1 (es)
CA (1) CA3199988A1 (es)
TW (1) TW202235080A (es)
WO (1) WO2022115545A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023009531A2 (pt) 2020-11-18 2023-10-03 Deciphera Pharmaceuticals Llc Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011470A (es) 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
WO2004112720A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Antiviral compositions and methods of using the same
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
US20150297593A1 (en) 2012-09-14 2015-10-22 Children's Medical Center Corporation Inhibition of viral infection-triggered asthma with c-kit inhibitor
KR20160122736A (ko) 2014-01-14 2016-10-24 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 이의 용도
SI3416957T1 (sl) 2016-02-19 2020-11-30 Sprint Bioscience Ab Spojine 6-heterociklil-4-morfolin-4-ilpiridin-2-ona, uporabne za zdravljenje raka in diabetesa
JP6997462B2 (ja) 2016-02-19 2022-01-17 スプリント バイオサイエンス アクティエボラーグ がんおよび糖尿病の治療に有用な６－アリール－４－モルホリン－１－イルピリドン化合物
HRP20220571T1 (hr) * 2017-08-23 2022-06-10 Sprint Bioscience Ab Spoj piridilpiridona
SG11202103404PA (en) 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
WO2022115545A1 (en) 2022-06-02
EP4251152A1 (en) 2023-10-04
JP2023553809A (ja) 2023-12-26
TW202235080A (zh) 2022-09-16
CN117083064A (zh) 2023-11-17
US11801238B2 (en) 2023-10-31
US20220184050A1 (en) 2022-06-16
CA3199988A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CR20230310A (es) Inhibidores de prmt5
PE20230238A1 (es) Inhibidores de kras g12c
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
AR119614A1 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
AR125120A1 (es) Actividad antiviral de inhibidores de vps34
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
PE20230601A1 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2021003202A1 (es) Compuestos de pirrolidina
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
AR127404A1 (es) Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
CO2023013321A2 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
AR125117A1 (es) Actividad antiviral de inhibidores de vps34
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR125118A1 (es) Actividad antiviral de inhibidores de vps34
AR125122A1 (es) Actividad antiviral de inhibidores de vps34
AR128106A1 (es) Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead